Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing

What Was Tested

This randomized controlled trial paper looks at Angiotensin II.

Who Took Part

According to the abstract, 24 subjects were involved.

By PubMed's age tags, the people studied were adults, men only.

The angiotensin II receptor blockade was assessed with two techniques, the reactive rise in plasma renin activity and an in vitro radioreceptor binding assay that quantified the displacement of angiotensin II by the blocking agents.

Measurements were obtained before and 4 and 24 hours after drug intake on days 1 and 8.

How the Study Was Run

In design terms this was a randomized, open-label and crossover study.

The subjects were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

Everyone knew when Angiotensin II was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include Angiotensin II, Angiotensin Receptor Antagonists, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Irbesartan and Losartan.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Angiotensin II in 24 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2002 (Clinical pharmacology and therapeutics), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.